Tenon Medical Inc(TNON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -47.46 | Insider Own | 8.38% | Shs Outstand | 2.7M | Perf Week | -11.68% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 77.08% | Insider Trans | -2.87% | Shs Float | 2.5M | Perf Month | -48.92% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -4.22 | Inst Own | 0.69% | Short Float | 2.11% | Perf Quarter | -71.85% |
| Income | -0.01B | P/S | 0.96 | EPS this Y | 64.29% | Inst Trans | 2.06% | Short Ratio | 0.01 | Perf Half Y | -92.71% |
| Sales | 0.01B | P/B | - | EPS next 5Y | 71.34% | ROA | -130.22% | Short Interest | 0.05M | Perf YTD | -94.32% |
| Book/sh | -14.57 | P/C | 3.03 | EPS past 3/5Y | 79.2% 16.41% | ROE | -551.19% | 52W High | -95.85% ($45.50) | Perf Year | -95.46% |
| Cash/sh | 0.62 | P/FCF | - | Sales past 3/5Y | 78.71% 145.95% | ROIC | - | 52W Low | -2.07% ($1.93) | Perf 3Y | -99.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 77.34% | Gross Margin | 66.81% | Volatility(W/M) | 9.77% 7.88% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 2.38 | Sales Y/Y TTM | 80.25% | Oper. Margin | -228.03% | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.48 | EPS Q/Q | 3.29% | Profit Margin | -257.85% | RSI (14) | 31.61 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.58 | Sales Q/Q | 126.77% | SMA20 | -26.28% ($2.56) | Beta | 1.42 | Target Price | $10.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/12 | SMA50 | -45.79% ($3.49) | Rel Volume | 0.01 | Prev Close | $1.93 |
| Employees | 26 | LT Debt/Eq | - | EPS/Sales Surpr. | -47.02% -16.95% | SMA200 | -88.73% ($16.77) | Avg Volume(3M) | 6.35M | Price | $1.89 |
| IPO | 2022/4/27 | Option/Short | No/Yes | Trades | 611 | Volume | 76,612 | Change | -2.07% |
Tenon Medical, Inc. (ticker) is a US small-cap medical device company that develops and sells the "Catamaran® SI Joint Fusion System," an implant for joint fusion surgery designed to treat sacroiliac (SI) joint problems that cause lower back and pelvic pain. The recent full launch of Catamaran SE and the acquisition of the SiVantage portfolio have expanded the company's product line, driving rapid revenue growth in 2025, positioning it as a growth-stage microcap stock.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 1% of its average volume.
Next earnings report: November 12
8 days to go.
TNON has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +64.3% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $96. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -99.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #123 of 140 in the industry
Based on market cap of $5M.
FAQ
What kind of company is TNON?
TNON belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of TNON?
The market cap of TNON is approximately $5M, ranking 5,612 within its sector.
What is the 52-week high and low for TNON?
TNON has recorded a 52-week high of $45.50 and a low of $1.93.
